FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Anthonius de Boer

Research Profile

Geographic Areas

Netherlands

Chemicals & Drugs

Disorders

Occupations

Pharmacogenetics

Concepts & Ideas

Procedures

Case Control Studies

Physiology

Genotype

Co-author Network

Publications

TOP 3
Danka J F Stuijver; Bregje van Zaane; Christof J Majoor; Patrick C Souverein; Harry R Büller; Anthonius de Boer; Olaf M Dekkers; Victor E A Gerdes
Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study.
Marieke T Blom; Anthonius de Boer; M L De Bruin; A W Hoes; Rudolph W Koster; F H Rutten; P C Souverein; Abdennasser Bardai; J Berdowski; M J Warnier; Hanno L Tan
Reduced in-hospital survival rates of out-of-hospital cardiac arrest victims with obstructive pulmonary disease.
Grace Wangge; Anthonius de Boer; Arno W Hoes; Olaf H Klungel; Mirjam J Knol
Expert-opinion on non-inferiority margin: a case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Anthonius de Boer (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Danka J F Stuijver; Bregje van Zaane; Christof J Majoor; Patrick C Souverein; Harry R Büller; Anthonius de Boer; Olaf M Dekkers; Victor E A Gerdes
Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study.
Chest 2013;143(5):1337-42.
2013: Marieke T Blom; Anthonius de Boer; M L De Bruin; A W Hoes; Rudolph W Koster; F H Rutten; P C Souverein; Abdennasser Bardai; J Berdowski; M J Warnier; Hanno L Tan
Reduced in-hospital survival rates of out-of-hospital cardiac arrest victims with obstructive pulmonary disease.
Resuscitation 2013;84(5):569-74.
2013: Grace Wangge; Anthonius de Boer; Arno W Hoes; Olaf H Klungel; Mirjam J Knol
Expert-opinion on non-inferiority margin: a case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery.
Thrombosis research 2013;131(4):368-71.
2013: A Lalmohamed; H G M Leufkens; Tjeerd P van Staa; P Vestergaard; Anthonius de Boer; E L Grove; P A F Jansen; F de Vries
Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement.
Journal of thrombosis and haemostasis : JTH 2013;11(4):642-50.
2013: M Sanni Ali; Wiebe R Pestman; Svetlana V Belitser; Anthonius de Boer; Rolf H H Groenwold; Arno W Hoes; Olaf Klungel
Time-dependent propensity score and collider-stratification bias: an example of beta2-agonist use and the risk of coronary heart disease.
European journal of epidemiology 2013;28(4):291-9.
2013: Ruben G Duijnhoven; Arno W Hoes; June M Raine; Sabine M J M Straus; Anthonius de Boer; Marie L De Bruin
Number of patients studied prior to approval of new medicines: a database analysis.
PLoS medicine 2013;10(3):e1001407.
2013: Grace Wangge; Kit C B Roes; Anthonius de Boer; Arno W Hoes; Mirjam J Knol
The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2013;185(3):222-7.
2013: Miriam J Warnier; Anthonius de Boer; Arno W Hoes; Jan A Kors; Mattijs E Numans; Frans H Rutten; Hanno L Tan; Marie L De Bruin
Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease.
COPD 2013;10(1):62-71.
2013: Seyed Hamidreza Mahmoudpour; Folkert W Asselbergs; Anthonius de Boer; Maarten Leusink; Ingrid Terreehorst; Lisa van der Putten; Anke Hilse Maitland-van der Zee
Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis.
Pharmacogenomics 2013;14(3):249-60.
2013: S Pouwels; J Verschuuren; Cyrus Cooper; Anthonius de Boer; D Hilton-Jones; M K Javaid; Hubert G M Leufkens; Frank de Vries
Fracture rate in patients with myasthenia gravis: the general practice research database.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2013;24(2):467-76.
2012: Rianne M F van Schie; Talitha I Verhoef; Loes E Visser; Judith A M Wessels; Peter N M Buhre; Anthonius de Boer; Albert Hofman; Saskia Le Cessie; Frits R Rosendaal; Tom Schalekamp; Martina Teichert; Felix J M van der Meer; Anke Hilse Maitland-van der Zee
Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose.
Pharmacogenomics 2012;13(16):1917-23.
2012: Arief Lalmohamed; Hubertus G M Leufkens; Tjeerd P van Staa; Peter Vestergaard; Cyrus Cooper; Anthonius de Boer; Frank de Vries
Timing of stroke in patients undergoing total hip replacement and matched controls: a nationwide cohort study.
Stroke; a journal of cerebral circulation 2012;43(12):3225-9.
2012: Talitha I Verhoef; Miranda J L Zuurhout; Anthonius de Boer; Saskia Le Cessie; William K Redekop; Tom Schalekamp; Felix J M van der Meer; Rianne M F van Schie; Anke Hilse Maitland-van der Zee
The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon.
British journal of clinical pharmacology 2012;74(6):1068-9.
2012: Miriam J Warnier; Anthonius de Boer; Arno W Hoes; Jan A Kors; Jan-Willem J Lammers; Frans H Rutten; Marie L de Bruin
Cardiac arrhythmias in adult patients with asthma.
The Journal of asthma : official journal of the Association for the Care of Asthma 2012;49(9):942-6.
2012: Arief Lalmohamed; Hubertus G M Leufkens; Tjeerd P van Staa; Peter Vestergaard; Anthonius de Boer; Erik Lerkevang Grove; Corinne Klop; Frank de Vries
Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study.
Archives of internal medicine 2012;172(16):1229-35.
2012: Sarah Kleijnen; Hubert G Leufkens; Bence Z Nagy; Boguslawa Osińska; Rafal Rdzany; Steffen Thirstrup; Pauline Vitré; Belen Corbacho; Anne d'Andon; Anthonius de Boer; Elisabeth George; Scott Goulden; Wim G Goettsch
Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2012;15(6):954-60.
2012: Talitha I Verhoef; Mia Wadelius; Samira Bayat; Ann K Daly; Anthonius de Boer; Mary Geitona; Elisabeth Haschke-Becher; Dyfrig A Hughes; Farhad Kamali; Lars-Åke Levin; Anke Hilse Maitland-van der Zee; Vangelis G Manolopoulos; Munir Pirmohamed; William K Redekop; Uwe Siebert; Julia C Stingl; Rianne Mf van Schie
Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs.
Pharmacogenomics 2012;13(12):1405-17.
2012: Rianne M F van Schie; Talitha I Verhoef; Judith A M Wessels; Peter N Buhre; Anthonius de Boer; Nadia el Khedr; Albert Hofman; Saskia Le Cessie; Anke Hilse Maitland-van der Zee; Frits R Rosendaal; Tom Schalekamp; Bruno H Stricker; Martina Teichert; Felix J M van der Meer; Loes E Visser
Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study.
Pharmacogenomics 2012;13(11):1239-45.
2012: R M F van Schie; T I Verhoef; J A M Wessels; A M V Babajeff; Anthonius de Boer; Saskia Le Cessie; Anke Hilse Maitland-van der Zee; Frits R Rosendaal; Tom Schalekamp; Felix J M van der Meer; Erik van Meegen
An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol.
Journal of thrombosis and haemostasis : JTH 2012;10(5):767-72.
2012: T I Verhoef; Loes E Visser; J A M Wessels; M M Buikema; Anthonius de Boer; Saskia Le Cessie; Anke Hilse Maitland-van der Zee; W K Redekop; Tom Schalekamp; M Teichert; Felix J M van der Meer; R M F Van Schie
Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.
Journal of thrombosis and haemostasis : JTH 2012;10(4):606-14.
2012: Ankie M Harmsze; Johannes C Kelder; Olaf H Klungel; Henk Ruven; Jurriën M ten Berg; Jochem W van Werkum; Heleen J Bouman; Nicoline J Breet; Anthonius de Boer; Christian M Hackeng; Vera H M Deneer
The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting.
Pharmacogenetics and genomics 2012;22(3):169-75.
2012: A Lalmohamed; W F Lems; P M J Welsing; Anthonius de Boer; J W G Jacobs; H Johansson; John A Kanis; Frank de Vries
Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fractures.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2012;23(3):861-9.
2011: Anthonius de Boer
When to publish measures of disproportionality derived from spontaneous reporting databases?
British journal of clinical pharmacology 2011;72(6):909-11.
2011: Rolf H H Groenwold; Arno W Hoes; Anthonius de Boer; Frank de Vries; Wiebe R Pestman; Frans H Rutten; Olaf Klungel
Balance measures for propensity score methods: a clinical example on beta-agonist use and the risk of myocardial infarction.
Pharmacoepidemiology and drug safety 2011;20(11):1130-7.
2011: Svetlana V Belitser; Anthonius de Boer; Rolf H H Groenwold; Edwin P Martens; Wiebe R Pestman; Olaf Klungel
Measuring balance and model selection in propensity score methods.
Pharmacoepidemiology and drug safety 2011;20(11):1115-29.
2011: Marloes Bazelier; Anthonius de Boer; Frank de Vries
Acid suppressants and hip fracture: duplicate publication bias?
Bone 2011;49(4):920; author reply 921.
2011: Rianne M F van Schie; Anthonius de Boer; Anke Hilse Maitland-van der Zee
Implementation of pharmacogenetics in clinical practice is challenging.
Pharmacogenomics 2011;12(9):1231-3.
2011: Anke Hilse Maitland-van der Zee; Bruce M Psaty; Paul Schiffers; Bruno Hch Stricker; Cornelia M van Duijn; Diane Bma van Wieren-de Wijer; Anthonius de Boer; Peter W de Leeuw; Rob G J H Janssen; Abraham A Kroon; Olaf Klungel
Genetic variation in the renin--angiotensin system, use of renin--angiotensin system inhibitors and the risk of myocardial infarction.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2011;12(3):208-14.
2011: Bas J M Peters; Helmi Pett; Bruce M Psaty; Bruno H Ch Stricker; Kerri L Wiggins; Joshua C Bis; Anthonius de Boer; Nicole L Glazer; Olaf Klungel; Anke Hilse Maitland-van der Zee
Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI.
Atherosclerosis 2011;217(2):458-64.
2011: Simone Eussen; Johan Garssen; Marcel L Bouvy; Anthonius de Boer; Johan J de Gier; Marco H Oosterveld; Cathy J M Rompelberg; Menno E van der Elst; Henk J van Kranen; Olaf Klungel
Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapy.
Pharmacoepidemiology and drug safety 2011;20(8):830-7.
2011: Rianne M F van Schie; Talitha I Verhoef; Judith A M Wessels; Anthonius de Boer; Saskia Le Cessie; Anke Hilse Maitland-van der Zee; Frits R Rosendaal; Tom Schalekamp; Felix J M van der Meer; Erik van Meegen
Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data.
European heart journal 2011;32(15):1909-17.
2011: Taina Mattila; Violeta Stoyanova; Anthonius de Boer; André Elferink; Christine C Gispen-de Wied; Tamar Wohlfarth
Insomnia medication: do published studies reflect the complete picture of efficacy and safety?
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2011;21(7):500-7.
2011: Maarten J Deenen; Valerie D Doodeman; Henk-Jan Guchelaar; Cornelis J A Punt; Jan H M Schellens; Paul H M Smits; Jolien Tol; Andrew Vincent; Jos H Beijnen; Artur M Burylo; Anthonius de Boer; Annemieke Cats
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(10):3455-68.
2011: Olav R de Peuter; Gregory Y H Lip; Patrick C Souverein; Olaf Klungel; Anthonius de Boer; Harry R Büller; Pieter W Kamphuisen
Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study.
European journal of heart failure 2011;13(5):489-95.
2011: S Pouwels; A Lalmohamed; P Souverein; Cyrus Cooper; B J Veldt; Hubert G M Leufkens; Anthonius de Boer; Tjeerd P van Staa; Frank de Vries
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2011;22(3):903-10.
2011: Bas J M Peters; Ankie M Harmsze; Jurriën M ten Berg; Anke Hilse Maitland-van der Zee; Mathieu M Tjoeng; Anthonius de Boer; Vera H M Deneer
CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
Pharmacogenomics 2011;12(2):141-4.
2011: Olav R de Peuter; Patrick C Souverein; Olaf Klungel; Harry R Büller; Anthonius de Boer; Pieter W Kamphuisen
Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure.
European journal of heart failure 2011;13(2):220-6.
2011: Hester L van den Hoek; Willem Jan W Bos; Anthonius de Boer; Ewoudt M W van de Garde
Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials.
BMJ (Clinical research ed.) 2011;343():d7281.
2011: Marieke T Blom; Anthonius de Boer; Hendrik de Jong; Sophia de Rooij; Mei-Ing Nieuwland; Anne M Spanjaart; Daniel A van Hoeijen; Barbara C van Munster; Abdennasser Bardai; Hanno L Tan
Differential changes in QTc duration during in-hospital haloperidol use.
PloS one 2011;6(9):e23728.
2011: Ankie M Harmsze; Mette Heringa; Henk Boot; Anthonius de Boer; Vera H M Deneer; Peter G M Mol; Tom Schalekamp; Monique M Verduijn; Freek W A Verheugt; Marianne le Comte
[Interaction between clopidogrel and proton pump inhibitors].
Nederlands tijdschrift voor geneeskunde 2011;155(28):A2442.
2011: Ankie M Harmsze; Jochem W van Werkum; Fulya Moral; Jurri N M Ten Berg; Christian M Hackeng; Olaf Klungel; Anthonius de Boer; Vera H M Deneer
Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients.
Platelets 2011;22(2):98-102.
2010: Taina K Mattila; Anthonius de Boer
Influence of intensive versus conventional glucose control on microvascular and macrovascular complications in type 1 and 2 diabetes mellitus.
Drugs 2010;70(17):2229-45.
2010: Simone Eussen; Menno E van der Elst; Olaf Klungel; Cathy J M Rompelberg; Johan Garssen; Marco H Oosterveld; Anthonius de Boer; Johan J de Gier; Marcel L Bouvy
A pharmaceutical care program to improve adherence to statin therapy: a randomized controlled trial.
The Annals of pharmacotherapy 2010;44(12):1905-13.
2010: Bas J M Peters; Andrei S Rodin; Olaf Klungel; Bruno H Ch Stricker; Anthonius de Boer; Anke Hilse Maitland-van der Zee
Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction.
Pharmacogenetics and genomics 2010;20(12):766-74.
2010: Ankie M Harmsze; Jochem W van Werkum; Jurriën M ten Berg; Bastiaan Zwart; Heleen J Bouman; Nicoline J Breet; Arnoud W J van 't Hof; Henk Ruven; Christian M Hackeng; Olaf Klungel; Anthonius de Boer; Vera H M Deneer
CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.
European heart journal 2010;31(24):3046-53.
2010: Grace Wangge; Olaf Klungel; K C B Roes; Anthonius de Boer; A W Hoes; M J Knol
Interpretation and inference in noninferiority randomized controlled trials in drug research.
Clinical pharmacology and therapeutics 2010;88(3):420-3.
2010: Talitha I Verhoef; Tom Schalekamp; William K Redekop; Anthonius de Boer; Anke Hilse Maitland-van der Zee
Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin.
Expert review of pharmacoeconomics & outcomes research 2010;10(4):375-8.
2010: Bas J M Peters; Andrei S Rodin; Olaf Klungel; Cornelia M van Duijn; Bruno H Ch Stricker; Ruben van't Slot; Anthonius de Boer; Anke Hilse Maitland-van der Zee
Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction.
Pharmacogenomics 2010;11(8):1065-76.
2010: Talitha I Verhoef; William K Redekop; Josep Darba; Mary Geitona; Dyfrig A Hughes; Uwe Siebert; Anthonius de Boer; Anke Hilse Maitland-van der Zee; Rita Barallon; Montserrat Briz; Ann Daly; Elisabeth Haschke-Becher; Farhad Kamali; Julia Kirchheiner; Vangelis G Manolopoulos; Munir Pirmohamed; Frits R Rosendaal; Rianne M F van Schie; Mia Wadelius
A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives.
Pharmacogenomics 2010;11(7):989-1002.
2010: Ankie M Harmsze; Karen Robijns; Jochem W van Werkum; Nicoline J Breet; Christian M Hackeng; Jurriën M ten Berg; Henk Ruven; Olaf Klungel; Anthonius de Boer; Vera H M Deneer
The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response.
Thrombosis and haemostasis 2010;103(5):920-5.
2010: Sander Pouwels; Arief Lalmohamed; Tjeerd P van Staa; Cyrus Cooper; Patrick Souverein; Hubertus G Leufkens; Lars Rejnmark; Anthonius de Boer; Peter Vestergaard; Frank de Vries
Use of organic nitrates and the risk of hip fracture: a population-based case-control study.
The Journal of clinical endocrinology and metabolism 2010;95(4):1924-31.
2010: Kim Taverne; Mark de Groot; Anthonius de Boer; Olaf Klungel
Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs.
Expert opinion on drug metabolism & toxicology 2010;6(4):439-60.
2010: Bas J M Peters; Andrei S Rodin; Anthonius de Boer; Anke Hilse Maitland-van der Zee
Methodological and statistical issues in pharmacogenomics.
The Journal of pharmacy and pharmacology 2010;62(2):161-6.
2010: Antoine C G Egberts; Anthonius de Boer
[Separate pharmaceutical budgets: skating on thin ice].
Nederlands tijdschrift voor geneeskunde 2010;154(51-52):A3004.
2010: Grace Wangge; Olaf Klungel; Kit C B Roes; Anthonius de Boer; Arno W Hoes; Mirjam J Knol
Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review.
PloS one 2010;5(10):e13550.
2010: Tom Schalekamp; Anthonius de Boer
Pharmacogenetics of oral anticoagulant therapy.
Current pharmaceutical design 2010;16(2):187-203.
2010: Ankie Harmsze; Jochem W van Werkum; Heleen J Bouman; Henk Ruven; Nicolien J Breet; Jurriën M ten Berg; Christian M Hackeng; Mathieu M Tjoeng; Olaf Klungel; Anthonius de Boer; Vera H M Deneer
Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.
Pharmacogenetics and genomics 2010;20(1):18-25.
2009: Rianne M F van Schie; M I A Wadelius; Farhad Kamali; Ann K Daly; Vangelis G Manolopoulos; Anthonius de Boer; Rita Barallon; Talitha I Verhoef; Julia Kirchheiner; Elisabeth Haschke-Becher; Montserrat Briz; Frits R Rosendaal; William K Redekop; Munir Pirmohamed; Anke-Hilse Maitland van der Zee
Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
Pharmacogenomics 2009;10(10):1687-95.
2009: Rianne M F van Schie; Andrea L Jorgensen; Anthonius de Boer; Anke Hilse Maitland-van der Zee
Systematic review of pharmacogenetic warfarin dosing.
Journal of general internal medicine 2009;24(10):1171.
2009: Sander Pouwels; Arief Lalmohamed; Bert Leufkens; Anthonius de Boer; Cyrus Cooper; Tjeerd P van Staa; Frank de Vries
Risk of hip/femur fracture after stroke: a population-based case-control study.
Stroke; a journal of cerebral circulation 2009;40(10):3281-5.
2009: Bas J M Peters; Olaf Klungel; Anthonius de Boer; Anke Hilse Maitland-van der Zee
Genetic determinants of response to statins.
Expert review of cardiovascular therapy 2009;7(8):977-83.
2009: Diane B M A van Wieren-de Wijer; Anke Hilse Maitland-van der Zee; Anthonius de Boer; Abraham A Kroon; Peter W de Leeuw; Paul Schiffers; Rob G J H Janssen; Bruce M Psaty; C.M. Duijn; Bruno H Ch Stricker; Olaf Klungel
Reasons for non-response in observational pharmacogenetic research.
Pharmacoepidemiology and drug safety 2009;18(8):665-71.
2009: Ozlem Bozkurt; Anthonius de Boer; Diederick Grobbee; Abraham A Kroon; Paul Schiffers; Peter de Leeuw; Olaf Klungel
Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2009;10(2):101-8.
2009: Ozlem Bozkurt; Anthonius de Boer; Diederick Grobbee; Peter W de Leeuw; Abraham A Kroon; Paul Schiffers; Olaf Klungel
Variation in Renin-Angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics.
American journal of hypertension 2009;22(5):545-51.
2009: Diane B M A van Wieren-de Wijer; Anke Hilse Maitland-van der Zee; Anthonius de Boer; Bruno H Ch Stricker; Abraham A Kroon; Peter W de Leeuw; Ozlem Bozkurt; Olaf Klungel
Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment.
Pharmacy world & science : PWS 2009;31(2):158-64.
2009: Bas J M Peters; Bruno H Ch Stricker; Anthonius de Boer; Olaf H Klungel; Anke Hilse Maitland-van der Zee
Pharmacogenetics of cardiovascular drug therapy.
Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases 2009;6(1):55-65.
2009: Bas Jm Peters; Olaf Klungel; Frank L Visseren; Anthonius de Boer; Anke Hilse Maitland-van der Zee
Pharmacogenomic insights into treatment and management of statin-induced myopathy.
Genome medicine 2009;1(12):120.
2009: D B M A van Wieren-de Wijer; Anke Hilse Maitland-van der Zee; Anthonius de Boer; Svetlana V Belitser; Abraham A Kroon; Peter W de Leeuw; P Schiffers; Rob G J H Janssen; C.M. Duijn; B H C H Stricker; Olaf Klungel
Determinants of DNA yield and purity collected with buccal cell samples.
European journal of epidemiology 2009;24(11):677-82.
2009: Diane B M A van Wieren-de Wijer; Anke Hilse Maitland-van der Zee; Anthonius de Boer; Abraham A Kroon; Peter W de Leeuw; Paul Schiffers; Rob G J H Janssen; Bruce M Psaty; C.M. Duijn; Bruno H Ch Stricker; Olaf Klungel
Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction.
Journal of hypertension 2009;27(1):61-8.
2008: Tom Schalekamp; Olaf Klungel; Patrick C Souverein; Anthonius de Boer
Effect of oral antiplatelet agents on major bleeding in users of coumarins.
Thrombosis and haemostasis 2008;100(6):1076-83.
2008: Hedi Schelleman; Olaf Klungel; J C M Witteman; Monique Breteler; Albert Hofman; C.M. Duijn; Anthonius de Boer; B H Ch Stricker
Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke.
The pharmacogenomics journal 2008;8(6):400-7.
2008: Ozlem Bozkurt; W M Monique Verschuren; B M A van Wieren-de Wijer; M J Knol; Anthonius de Boer; Diederick Grobbee; M I Geerlings; Eibert Heerdink; Olaf Klungel
Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives.
Journal of human hypertension 2008;22(11):774-80.
2008: Willem M Otte; Frank van der Maas; Anthonius de Boer
Comparison of knowledge and accessibility to information sources of HIV/AIDS between blind and sighted populations in Nigeria.
AIDS care 2008;20(9):1093-7.
2008: Edwin P Martens; Wiebe R Pestman; Anthonius de Boer; Svetlana V Belitser; Olaf Klungel
Systematic differences in treatment effect estimates between propensity score methods and logistic regression.
International journal of epidemiology 2008;37(5):1142-7.
2008: Tom Schalekamp; Anke Hilse Maitland-van der Zee; Anthonius de Boer
Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9?
Thrombosis and haemostasis 2008;100(2):175-6.
2008: Bas J M Peters; Anke Hilse Maitland-van der Zee; Bruno H Ch Stricker; Diane B M A van Wieren-de Wijer; Anthonius de Boer; Abraham A Kroon; Peter W de Leeuw; Paul Schiffers; Rob G J H Janssen; C.M. Duijn; Olaf Klungel
Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant.
Pharmacogenetics and genomics 2008;18(7):631-6.
2008: Tom Schalekamp; Olaf Klungel; Patrick C Souverein; Anthonius de Boer
Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins.
Archives of internal medicine 2008;168(2):180-5.
2008: Sabine J G M Ahlers; Laura van Gulik; Aletta M van der Veen; Hendricus P A van Dongen; Peter Bruins; Svetlana V Belitser; Anthonius de Boer; Dick Tibboel; Catherijne A J Knibbe
Comparison of different pain scoring systems in critically ill patients in a general ICU.
Critical care (London, England) 2008;12(1):R15.
2008: Edwin P Martens; Anthonius de Boer; Wiebe R Pestman; Svetlana V Belitser; Bruno H Ch Stricker; Olaf Klungel
Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods.
Pharmacoepidemiology and drug safety 2008;17(1):1-8.
2007: Pearl D Gumbs; W M Monique Verschuren; Patrick C Souverein; Aukje K Mantel-Teeuwisse; ardine de wit; Anthonius de Boer; Olaf Klungel
Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution.
British journal of clinical pharmacology 2007;64(5):680-5.
2007: Menno E van der Elst; Marcel L Bouvy; Cornelis J de Blaey; Anthonius de Boer
Effect of drug combinations on admission for recurrent myocardial infarction.
Heart (British Cardiac Society) 2007;93(10):1226-30.
2007: Hedi Schelleman; Olaf Klungel; Jacqueline C M Witteman; Monique Breteler; Albert Hofman; C.M. Duijn; Anthonius de Boer; Bruno H Ch Stricker
Diuretic-gene interaction and the risk of myocardial infarction and stroke.
The pharmacogenomics journal 2007;7(5):346-52.
2007: Hedi Schelleman; Olaf Klungel; Jacqueline C M Witteman; Albert Hofman; C.M. Duijn; Anthonius de Boer; Bruno H Ch Stricker
Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or beta-blockers and the risk of atherosclerosis.
British journal of clinical pharmacology 2007;64(1):57-66.
2007: Suzanne V Frankfort; Bregje A Appels; Anthonius de Boer; Linda R Tulner; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen; B A Schmand
Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.
Pharmacoepidemiology and drug safety 2007;16(5):545-51.
2007: Tom Schalekamp; Johanna H H van Geest-Daalderop; Mark H H Kramer; Angelique T M van Holten-Verzantvoort; Anthonius de Boer
Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction.
European journal of clinical pharmacology 2007;63(4):335-43.
2007: Hedi Schelleman; Olaf Klungel; Jacqueline C M Witteman; Monique Breteler; Mojgan Yazdanpanah; Alexander Hessel Jan Danser; Albert Hofman; C.M. Duijn; Anthonius de Boer; Bruno H Ch Stricker
Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers.
European journal of human genetics : EJHG 2007;15(4):478-84.
2007: Boris L G Van Wijk; Jerry Avorn; Daniel H Solomon; Olaf Klungel; Eibert Heerdink; Anthonius de Boer; Maurice Brookhart
Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study.
Journal of hypertension 2007;25(3):689-97.
2007: Tom Schalekamp; B P Brassé; Janine F M Roijers; Erik van Meegen; Felix J M van der Meer; E M van Wijk; Toine Egberts; Anthonius de Boer
VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement.
Clinical pharmacology and therapeutics 2007;81(2):185-93.
2007: Ozlem Bozkurt; Anthonius de Boer; Diederick Grobbee; Eibert Heerdink; Huib Burger; Olaf Klungel
Pharmacogenetics of glucose-lowering drug treatment: a systematic review.
Molecular diagnosis & therapy 2007;11(5):291-302.
2007: Pearl D Gumbs; Monique W M Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Anthonius de Boer; Olaf Klungel
Economic evaluations of cholesterol-lowering drugs: a critical and systematic review.
PharmacoEconomics 2007;25(3):187-99.
2006: Tom Schalekamp; Carolien Smit; Johanna H H van Geest-Daalderop; Hanneke de Vries-Goldschmeding; Anthonius de Boer
Discrepancies between medication records of anticoagulation clinics and pharmacy records.
Pharmacoepidemiology and drug safety 2006;15(11):823-8.
2006: Boris L G Van Wijk; Olaf Klungel; Eibert Heerdink; Anthonius de Boer
Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy.
Pharmacoepidemiology and drug safety 2006;15(8):587-93.
2006: Tom Schalekamp; Bjorn P Brassé; Janine F M Roijers; Youssef Chahid; Johanna H H van Geest-Daalderop; Hanneke de Vries-Goldschmeding; Eduard M van Wijk; Toine Egberts; Anthonius de Boer
VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.
Clinical pharmacology and therapeutics 2006;80(1):13-22.
2006: Hedi Schelleman; Olaf Klungel; Jacqueline C M Witteman; Albert Hofman; C.M. Duijn; Anthonius de Boer; Bruno H Ch Stricker
The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure.
European journal of human genetics : EJHG 2006;14(7):860-6.
2006: Anke Hilse Maitland-van der Zee; J Wouter Jukema; Aeilko H Zwinderman; D Michael Hallman; Anthonius de Boer; John J P Kastelein; Peter de Knijff
Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS).
Acta cardiologica 2006;61(3):327-31.
2006: Suzanne V Frankfort; Bregje A Appels; Anthonius de Boer; Linda R Tulner; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen
Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
International journal of clinical practice 2006;60(6):646-54.
2006: Tom Schalekamp; Gerard J J Boink; Loes E Visser; Bruno H Ch Stricker; Anthonius de Boer; Olaf Klungel
CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?
Clinical pharmacology and therapeutics 2006;79(6):511-20.
2006: Aukje K Mantel-Teeuwisse; Olaf Klungel; Albert Hofman; W M Monique Verschuren; Paul H Trienekens; Arijan J Porsius; Bruno H Ch Stricker; Anthonius de Boer
Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999).
British journal of clinical pharmacology 2006;61(5):592-600.
2006: Edwin P Martens; Wiebe R Pestman; Anthonius de Boer; Svetlana V Belitser; Olaf Klungel
Instrumental variables: application and limitations.
Epidemiology (Cambridge, Mass.) 2006;17(3):260-7.
2006: Menno E van der Elst; Marcel L Bouvy; Cornelis J de Blaey; Anthonius de Boer
Improving pharmacotherapy after myocardial infarction by group academic detailing using feedback data on a patient level.
Pharmacotherapy 2006;26(2):254-9.
2006: Hedi Schelleman; Olaf Klungel; C.M. Duijn; Jacqueline C M Witteman; Albert Hofman; Anthonius de Boer; Bruno H Ch Stricker
Drug-gene interaction between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and antihypertensive therapy.
The Annals of pharmacotherapy 2006;40(2):212-8.
2006: Pearl D Gumbs; W M Monique Verschuren; Aukje K Mantel-Teeuwisse; Ardine G de Wit; Albert Hofman; Paul H Trienekens; Bruno H Ch Stricker; Anthonius de Boer; Olaf Klungel
Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study.
Drugs & aging 2006;23(9):733-41.
2006: Boris L G Van Wijk; Olaf Klungel; Eibert Heerdink; Anthonius de Boer
A comparison of two multiple-characteristic decision-making models for the comparison of antihypertensive drug classes: Simple Additive Weighting (SAW) and Technique for Order Preference by Similarity to an Ideal Solution (TOPSIS).
American journal of cardiovascular drugs : drugs, devices, and other interventions 2006;6(4):251-8.
2006: Boris L G Van Wijk; Olaf Klungel; Eibert Heerdink; Anthonius de Boer
Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation.
Journal of clinical epidemiology 2006;59(1):11-7.
2006: Hedi Schelleman; Bruno H Ch Stricker; W M Monique Verschuren; Anthonius de Boer; A A Kroon; Peter W de Leeuw; D Kromhout; Olaf Klungel
Interactions between five candidate genes and antihypertensive drug therapy on blood pressure.
The pharmacogenomics journal 2006;6(1):22-6.
2006: Boris L G Van Wijk; Olaf Klungel; Eibert Heerdink; Anthonius de Boer
Generic substitution of antihypertensive drugs: does it affect adherence?
The Annals of pharmacotherapy 2006;40(1):15-20.
2005: Suzanne V Frankfort; Bregje A Appels; Anthonius de Boer; Linda R Tulner; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen
Discontinuation of rivastigmine in routine clinical practice.
International journal of geriatric psychiatry 2005;20(12):1167-71.
2005: Menno E van der Elst; Marcel L Bouvy; Cornelis J de Blaey; Anthonius de Boer
Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis.
Clinical therapeutics 2005;27(11):1806-14.
2005: Boris L G Van Wijk; Olaf Klungel; Eibert Heerdink; Anthonius de Boer
Rate and determinants of 10-year persistence with antihypertensive drugs.
Journal of hypertension 2005;23(11):2101-7.
2005: Igor Schillevoort; Ron Herings; G W K Hugenholtz; Anthonius de Boer; Willem A Nolen; Raymund A C Roos; Hubert G M Leufkens
Antipsychotic-induced extrapyramidal syndromes in psychiatric practice: a case-control study.
Pharmacy world & science : PWS 2005;27(4):285-9.
2005: Aukje K Mantel-Teeuwisse; Olaf Klungel; Tom Schalekamp; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Suboptimal choices and dosing of statins at start of therapy.
British journal of clinical pharmacology 2005;60(1):83-9.
2005: Stefan R Florentinus; Eibert Heerdink; Anthonius de Boer; Liset Van Dijk; Hubert G M Leufkens
The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
Pharmacoepidemiology and drug safety 2005;14(7):437-41.
2005: Paul Hommerson; Srecko I Nedeljkovic; Olaf Klungel; Anthonius de Boer; Miodrag Ostojic; Miodrag Z Grujic; Nikola Vojvodic; Bennie P M Bloemberg; Daan Kromhout
Cardiovascular drug use and differences in the incidence of cardiovascular mortality in elderly Serbian men.
Pharmacy world & science : PWS 2005;27(2):124-8.
2005: Hedi Schelleman; Olaf Klungel; C.M. Duijn; Jacqueline C M Witteman; Albert Hofman; Anthonius de Boer; Bruno H Ch Stricker
Insertion/deletion polymorphism of the ACE gene and adherence to ACE inhibitors.
British journal of clinical pharmacology 2005;59(4):483-5.
2005: Boris L G Van Wijk; Olaf Klungel; Eibert Heerdink; Anthonius de Boer
Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review.
The Annals of pharmacotherapy 2005;39(2):319-28.
2004: Olaf Klungel; Edwin P Martens; Bruce M Psaty; Diederick Grobbee; Sean D Sullivan; Bruno H Ch Stricker; Hubert G M Leufkens; Anthonius de Boer
Methods to assess intended effects of drug treatment in observational studies are reviewed.
Journal of clinical epidemiology 2004;57(12):1223-31.
2004: Tom Schalekamp; Mirjam Oosterhof; Erik van Meegen; Felix J M van der Meer; Jean Conemans; Mirjam Hermans; Irma Meijerman; Anthonius de Boer
Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status.
Clinical pharmacology and therapeutics 2004;76(5):409-17.
2004: Stefan R Florentinus; Eibert Heerdink; Olaf Klungel; Anthonius de Boer
Should rosuvastatin be withdrawn from the market?
Lancet 2004;364(9445):1577; author reply 1578-9.
2004: David A M C van de Vijver; Raymund A C Roos; P A F Jansen; Arijan J Porsius; Anthonius de Boer
Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment?
Pharmacy world & science : PWS 2004;26(5):277-81.
2004: der Zee Anke-Hilse Maitland-van; Olaf Klungel; Anthonius de Boer
Pharmacogenetics in health-care practice.
Pharmacy world & science : PWS 2004;26(5):253-5.
2004: Aukje K Mantel-Teeuwisse; W M Monique Verschuren; Olaf Klungel; Anthonius de Boer; Daan Kromhout
Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands.
British journal of clinical pharmacology 2004;58(3):310-6.
2004: Boris L G Van Wijk; Olaf Klungel; Eibert Heerdink; Anthonius de Boer
The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen.
Journal of hypertension 2004;22(9):1831-7.
2004: Aukje K Mantel-Teeuwisse; Wim G Goettsch; Olaf Klungel; Anthonius de Boer; Ron Herings
Long term persistence with statin treatment in daily medical practice.
Heart (British Cardiac Society) 2004;90(9):1065-6.
2004: Martine E C van Eijk; Arsenio H P Paes; Arijan J Porsius; Jerry Avorn; Anthonius de Boer
Pre-randomization decisions and group stratification in a randomized controlled trial to improve prescribing.
Pharmacy world & science : PWS 2004;26(4):227-31.
2004: Tom Schalekamp; Johanna H H van Geest-Daalderop; Hanneke de Vries-Goldschmeding; Jean Conemans; M j Bernsen Mj; Anthonius de Boer
Acenocoumarol stabilization is delayed in CYP2C93 carriers.
Clinical pharmacology and therapeutics 2004;75(5):394-402.
2004: Hedi Schelleman; Olaf Klungel; D Kromhout; Anthonius de Boer; Bruno H Ch Stricker; W M Monique Verschuren
Prevalence and determinants of undertreatment of hypertension in the Netherlands.
Journal of human hypertension 2004;18(5):317-24.
2004: M M R de Maat; Anthonius de Boer; Cornelis H W Koks; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Albert T A Mairuhu; Alwin D R Huitema; J H Beijnen
Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care.
Journal of clinical pharmacy and therapeutics 2004;29(2):121-30.
2004: Anke Hilse Maitland-van der Zee; Olaf Klungel; Bruno H Ch Stricker; W M Monique Verschuren; Jacqueline C M Witteman; Theo Stijnen; Albert Hofman; Monique Breteler; Hubert G M Leufkens; Anthonius de Boer
Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness.
Journal of clinical epidemiology 2004;57(3):237-42.
2004: Hedi Schelleman; Bruno H Ch Stricker; Anthonius de Boer; Abraham A Kroon; Monique W M Verschuren; C.M. Duijn; Bruce M Psaty; Olaf Klungel
Drug-gene interactions between genetic polymorphisms and antihypertensive therapy.
Drugs 2004;64(16):1801-16.
2004: Anke Hilse Maitland-van der Zee; Olaf Klungel; Bruno H Ch Stricker; David L Veenstra; John J P Kastelein; Albert Hofman; Jacqueline C M Witteman; Hubert G M Leufkens; C.M. Duijn; Anthonius de Boer
Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men.
Pharmacogenetics 2004;14(1):53-60.
2004: Aukje K Mantel-Teeuwisse; Olaf Klungel; Toine Egberts; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin.
Drug safety : an international journal of medical toxicology and drug experience 2004;27(1):63-70.
2003: Menno E van der Elst; Henk Buurma; Marcel L Bouvy; Anthonius de Boer
Drug therapy for prevention of recurrent myocardial infarction.
The Annals of pharmacotherapy 2003;37(10):1465-77.
2003: Wim J Tamminga; Johan Wemer; Berend Oosterhuis; Anthonius de Boer; Stan Vranckx; Ben F H Drenth; Rokus A de Zeeuw; Lou F M H De Leij; Jan H G Jonkman
Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study.
European journal of clinical pharmacology 2003;59(1):57-64.
2003: Anke Hilse Maitland-van der Zee; Olaf Klungel; Bruno H Ch Stricker; Deirdre A M van der Kuip; Jacqueline C M Witteman; Albert Hofman; Hubert G M Leufkens; Anthonius de Boer
Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study.
Pharmacy world & science : PWS 2003;25(2):70-2.
2003: Aukje K Mantel-Teeuwisse; W M Monique Verschuren; Olaf Klungel; Daan Kromhout; A D Lindemans; J Avorn; Arijan J Porsius; Anthonius de Boer
Undertreatment of hypercholesterolaemia: a population-based study.
British journal of clinical pharmacology 2003;55(4):389-97.
2003: Anke Hilse Maitland-van der Zee; Bruno H Ch Stricker; Olaf Klungel; Aukje K Mantel-Teeuwisse; John J P Kastelein; Albert Hofman; Hubert G M Leufkens; C.M. Duijn; Anthonius de Boer
Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes.
Pharmacogenetics 2003;13(4):219-23.
2003: Monique M R de Maat; Daniël M Jonker; Cornelis H W Koks; Pieter L Meenhorst; Jan W Mulder; Teun M Post; Eric C M van Gorp; Anthonius de Boer; Jos H Beijnen
Pharmacotherapy of Hospitalised HIV-Infected Patients in a General Hospital during 1990, 1997 and 2001.
Clinical drug investigation 2003;23(1):45-53.
2003: Menno E van der Elst; Nelly Cisneros-Gonzalez; Cornelis J de Blaey; Henk Buurma; Anthonius de Boer
Oral antithrombotic use among myocardial infarction patients.
The Annals of pharmacotherapy 2003;37(1):143-6.
2002: Aukje K Mantel-Teeuwisse; Olaf Klungel; Ron Herings; Eugène P van Puijenbroek; Arijan J Porsius; Anthonius de Boer
Myopathy due to statin/fibrate use in the Netherlands.
The Annals of pharmacotherapy 2002;36(12):1957-60.
2002: Anke Hilse Maitland-van der Zee; Bruno H Stricker; Olaf Klungel; John J Kastelein; Albert Hofman; Jacqueline C M Witteman; Monique Breteler; Hubertus G Leufkens; C.M. Duijn; Anthonius de Boer
The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype.
Pharmacogenetics 2002;12(8):647-53.
2002: Martine E C van Eijk; S V Belitser; Arijan J Porsius; Anthonius de Boer
Evaluation of patient outcomes in an area where prescribing of anticholinergic antidepressants was influenced by academic detailing.
Pharmacy world & science : PWS 2002;24(4):144-8.
2002: David A M C van de Vijver; Raymund A C Roos; P A F Jansen; Arijan J Porsius; Anthonius de Boer
Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa.
British journal of clinical pharmacology 2002;54(2):168-70.
2002: Anke Hilse Maitland-van der Zee; Olaf Klungel; Bruno H Ch Stricker; W M Monique Verschuren; John J P Kastelein; Hubert G M Leufkens; Anthonius de Boer
Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors.
Atherosclerosis 2002;163(2):213-22.
2002: David A M C van de Vijver; Raymund A C Roos; P A F Jansen; Arijan J Porsius; Anthonius de Boer
Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment.
European journal of clinical pharmacology 2002;58(2):157-61.
2002: Olaf Klungel; Susan R Heckbert; Anthonius de Boer; Hubert G M Leufkens; Sean D Sullivan; Paul A Fishman; David L Veenstra; Bruce M Psaty
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
The Annals of pharmacotherapy 2002;36(5):751-7.
2002: Aukje K Mantel-Teeuwisse; Olaf Klungel; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?
British journal of clinical pharmacology 2002;53(4):379-85.
2002: Igor Schillevoort; Anthonius de Boer; Jan van der Weide; Linda S W Steijns; Raymund A C Roos; P A F Jansen; Hubert G M Leufkens
Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study.
Pharmacogenetics 2002;12(3):235-40.
2002: Monique M R de Maat; Suzanne V Frankfort; Ron A A Mathôt; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Cornelis H W Koks; Richard Hoetelmans; Anthonius de Boer; Jos H Beijnen
Discrepancies between medical and pharmacy records for patients on anti-HIV drugs.
The Annals of pharmacotherapy 2002;36(3):410-5.
2002: Igor Schillevoort; Eugène P van Puijenbroek; Anthonius de Boer; Raymund A C Roos; P A F Jansen; Hubert G M Leufkens
Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports.
International clinical psychopharmacology 2002;17(2):75-9.
2002: David A M C van de Vijver; Raymund A C Roos; P A F Jansen; Arijan J Porsius; Anthonius de Boer
Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users.
Acta neurologica Scandinavica 2002;105(1):8-12.
2001: Igor Schillevoort; Anthonius de Boer; Ron Herings; Raymund A C Roos; P A F Jansen; Hubert G M Leufkens
Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine.
The Annals of pharmacotherapy 2001;35(12):1517-22.
2001: Martine E C van Eijk; L F Krist; Jerry Avorn; Arijan J Porsius; Anthonius de Boer
Do the research goal and databases match? A checklist for a systematic approach.
Health policy (Amsterdam, Netherlands) 2001;58(3):263-74.
2001: Aukje K Mantel-Teeuwisse; Olaf Klungel; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer
Comparison of different methods to estimate prevalence of drug use by using pharmacy records.
Journal of clinical epidemiology 2001;54(11):1181-6.
2001: David A M C van de Vijver; Raymund A C Roos; P A F Jansen; Arijan J Porsius; Anthonius de Boer
Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records.
Pharmacoepidemiology and drug safety 2001;10(6):549-54.
2001: Anke Hilse Maitland-van der Zee; Olaf Klungel; J M Kloosterman; jacob seidell; Hubert G M Leufkens; Anthonius de Boer
The association between antihypertensive drug therapies and plasma lipid levels in the general population.
Journal of human hypertension 2001;15(10):701-5.
2001: David A M C van de Vijver; Bruno H Ch Stricker; Monique Breteler; Raymund A C Roos; Arijan J Porsius; Anthonius de Boer
Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease.
Pharmacy world & science : PWS 2001;23(4):148-52.
2001: Igor Schillevoort; Anthonius de Boer; Ron Herings; Raymund A C Roos; P A F Jansen; Hubert G M Leufkens
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.
European journal of clinical pharmacology 2001;57(4):327-31.
2001: Olaf Klungel; B H Stricker; Monique Breteler; jacob seidell; Bruce M Psaty; Anthonius de Boer
Is drug treatment of hypertension in clinical practice as effective as in randomized controlled trials with regard to the reduction of the incidence of stroke?
Epidemiology (Cambridge, Mass.) 2001;12(3):339-44.
2001: Martine E C van Eijk; Jerry Avorn; Arijan J Porsius; Anthonius de Boer
Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing.
BMJ (Clinical research ed.) 2001;322(7287):654-7.
2001: Aukje K Mantel-Teeuwisse; J M Kloosterman; Anke Hilse Maitland-van der Zee; Olaf Klungel; Arijan J Porsius; Anthonius de Boer
Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels.
Drug safety : an international journal of medical toxicology and drug experience 2001;24(6):443-56.
2000: Olaf Klungel; Anthonius de Boer; Arsenio H P Paes; NJ Nagelkerke; jacob seidell; Albert Bakker
Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure.
Journal of clinical epidemiology 2000;53(11):1158-63.
2000: Olaf Klungel; Arsenio H P Paes; Anthonius de Boer; Marijke M Kuyvenhoven; jacob seidell; Albert Bakker
Sex differences in the medication choice for hypertension in general practice. A study with written case simulations.
Pharmacy world & science : PWS 2000;22(4):140-6.
2000: Martine E C van Eijk; P Bahri; G Dekker; Ron Herings; Arijan J Porsius; Jerry Avorn; Anthonius de Boer
Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects.
Journal of clinical epidemiology 2000;53(6):645-51.
2000: HS Lau; C Florax; Arijan J Porsius; Anthonius de Boer
The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards.
British journal of clinical pharmacology 2000;49(6):597-603.
2000: Olaf Klungel; Anthonius de Boer; Arsenio H P Paes; Ron Herings; jacob seidell; Albert Bakker
Influence of question structure on the recall of self-reported drug use.
Journal of clinical epidemiology 2000;53(3):273-7.
2000: HS Lau; J Riezebos; V Abas; Arijan J Porsius; Anthonius de Boer
A nation-wide study on the practice of euthanasia and physician-assisted suicide in community and hospital pharmacies in The Netherlands.
Pharmacy world & science : PWS 2000;22(1):3-9.
2000: Olaf Klungel; Anthonius de Boer; Arsenio H P Paes; NJ Nagelkerke; jacob seidell; Albert Bakker
Influence of correction for within-person variability in blood pressure on the prevalence, awareness, treatment, and control of hypertension.
American journal of hypertension 2000;13(1 Pt 1):88-91.
1999: Olaf Klungel; Anthonius de Boer; Arsenio H P Paes; jacob seidell; Albert Bakker
Cardiovascular diseases and risk factors in a population-based study in The Netherlands: agreement between questionnaire information and medical records.
The Netherlands journal of medicine 1999;55(4):177-83.
1999: Olaf Klungel; Anthonius de Boer; Arsenio H P Paes; Ron Herings; jacob seidell; Albert Bakker
Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands.
Pharmacy world & science : PWS 1999;21(5):217-20.
1999: Marcel L Bouvy; Eibert Heerdink; Olaf Klungel; Anthonius de Boer; A G Stuurman-Bieze; H G Leufkens
Women with angina pectoris receive less antiplatelet treatment than men.
The British journal of general practice : the journal of the Royal College of General Practitioners 1999;49(441):299-300.
1998: Olaf Klungel; jacob seidell; Anthonius de Boer
Overestimation of the prevalence of hypertension in the population.
Journal of hypertension 1998;16(11):1702-3.
1998: Olaf Klungel; Anthonius de Boer; Arsenio H P Paes; jacob seidell; Albert Bakker
Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension.
Journal of hypertension 1998;16(10):1545-53.
1998: Olaf Klungel; Anthonius de Boer; Arsenio H P Paes; jacob seidell; NJ Nagelkerke; Albert Bakker
Undertreatment of hypertension in a population-based study in The Netherlands.
Journal of hypertension 1998;16(9):1371-8.
1998: Olaf Klungel; jacob seidell; Anthonius de Boer
Assessment of control of hypertension in the population.
Journal of hypertension 1998;16(3):395-6.
1997: Anthonius de Boer; Arijan J Porsius
Why do scientists still study and discuss homeopathy?
Pharmacy world & science : PWS 1997;19(4):176-7.
1997: Olaf Klungel; Anthonius de Boer; Arsenio H P Paes; jacob seidell; Albert Bakker
Sex differences in the pharmacological treatment of hypertension: a review of population-based studies.
Journal of hypertension 1997;15(6):591-600.
1997: HS Lau; Anthonius de Boer; K S Beuning; Arijan J Porsius
Validation of pharmacy records in drug exposure assessment.
Journal of clinical epidemiology 1997;50(5):619-25.
1996: H A Tissot van Patot; J A Leusink; J Roodenburg; B M de Jongh; H S Lau; S de Boer; Anthonius de Boer
Selective decontamination of the digestive tract: effect of cessation of routine application at an ICU.
Pharmacy world & science : PWS 1996;18(5):171-7.
1996: H S Lau; K S Beuning; E Postma-Lim; L Klein-Beernink; Anthonius de Boer; A J Porsius
Non-compliance in elderly people: evaluation of risk factors by longitudinal data analysis.
Pharmacy world & science : PWS 1996;18(2):63-8.
1996: Ron Herings; B H Stricker; Anthonius de Boer; Albert Bakker; F Sturmans; A Stergachis
Current use of thiazide diuretics and prevention of femur fractures.
Journal of clinical epidemiology 1996;49(1):115-9.
1995: Ron Herings; B H Stricker; Anthonius de Boer; Albert Bakker; F Sturmans
Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life.
Archives of internal medicine 1995;155(16):1801-7.
1995: Ron Herings; Anthonius de Boer; B H Stricker; Hubert G M Leufkens; A Porsius
Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme.
Lancet 1995;345(8959):1195-8.
1995: Ron Herings; Anthonius de Boer; B H Stricker; Albert Bakker; F Sturmans
A rapid method to estimate the incidence rate and prevalence of insulin-dependent diabetes mellitus in children 0-19 years of age.
Pharmacy world & science : PWS 1995;17(1):17-9.
1993: Anthonius de Boer; Ron Herings
Oral contraceptives without prescription.
Lancet 1993;342(8877):993.